Sangamo Therapeutics to Announce Q1 Earnings on May 14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: seekingalpha
- Earnings Announcement Date: Sangamo Therapeutics (SGMO) is set to release its Q1 2023 earnings on May 14 after market close, with consensus EPS estimated at $0.04 and revenue projected at $33.73 million, reflecting a substantial 427% year-over-year increase.
- Performance Expectations: Over the past year, SGMO has only beaten EPS and revenue estimates 25% of the time, indicating challenges in profitability and revenue growth that could impact investor confidence moving forward.
- Estimate Revision Trends: In the last three months, EPS estimates saw no upward revisions and one downward revision, while revenue estimates experienced one upward and one downward revision, suggesting instability in market expectations regarding the company's future performance.
- Market Response: Despite facing performance pressures, Sangamo is advancing its neurology pipeline and targeting a Fabry BLA submission, demonstrating ongoing commitment to R&D efforts that may lay the groundwork for future growth.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
